Urethral cancer is very rare disease, accounting for less than 0.5% of incidences of malignancies. Data on its management are scarce due to the rare nature of the cases. We present a 34-year-old man, who presented to our hospital with a month history of hematuria. He had no lower urinary tract symptoms and no significant risk factors for urothelial cancer. He was evaluated and found to have lesions in the posterior urethra on urethrocytoscopy, biopsy of which revealed a low-grade urothelial cancer. He was counselled and had 6 courses of intraurethral instillation of 40mg of Mitomycin-C diluited in 50mL of saline held in the urethra with penile clamp for 30 minutes. The hematuria stopped after the second course, a repeat urethrocystoscopy 6 months after the completion of the chemotherapy, showed resolution of the lesion and repeat biopsy showed no evidence of malignancy. However, the patient developed short segment partial penile urethral stricture that was treated with dilatation. In conclusion, low-grade urothelial cancer of the urethra can be successfully cured with Intraurethral instillation of Mitomycin-C, without prior transurethral resection.
Introduction
Urethral cancer is very rare condition, accounting for less than 0.5% of incidences of malignancies. 1 There is generally a scarce data on its management due to the rare nature of the disease. About 55-65% of the urothelial cancers are located in the posterior; and the bulbar parts of the urethra, while 30-35% occur in the remaining anterior urethra. 2 Several treatment modalities for urethral cancer had been described. These include transurethral resection, 3 radiotherapy, chemotherapy and combination therapy. 4, 5 They can all be effectively used in treating patients with this condition. Some authors have reported successful use of intraurethral instillation of Mitomycin C. 3, 6 Mitomycin C is an antitumor antibiotic that is isolated from Streptomyces caespitosus. It is one of the most important chemotherapeutical agents that is used for urothelial cancers. 6, 7 It acts by selectively inhibiting the synthesis of Deoxyribonucleic acid (DNA). High concentration of Mitomycin C suppresses both ribonucleic acid (RNA) and protein synthesis.
The use of intraurethral mitomycin C instillation, appears attractive due to relative ease of the procedure, however it is associated with some complications. 3 Here we present a rare case of low-grade transitional cell carcinoma of the urethra that was successfully treated with intraurethral instillation of mitomycin C, without prior transurethral resection or fulguration.
Case Report
BK is a 34-year-old man, who presented to our outpatient clinic with a month history of hematuria. He had no lower urinary tract symptoms, no previous history of hematuria and no significant risk factors for urothelial cancer.
Physical examination revealed a young man with normal findings in both general and systemic examinations, however urethrocystoscopy revealed lesions in the posterior urethra just proximal to the verumentanum, with normal looking bladder wall. Biopsy of the earlier noticed lesion revealed a low-grade urothelial carcinoma ( Figure 1 ). Intravenous urography revealed no upper tract involvement .
He was counselled, prepared and had intraurethral instillation of 40 mg of Mitomycin C, diluted in 50 mL of saline, which was held up in the urethra for 30 minutes, using a penile clamp. A total of 6 courses were given at weekly intervals. The hematuria stopped after the second course, but he developed irritative lower urinary tract symptoms which resolved a couple of weeks after the completion of the chemotherapy. Six months later when he came for a check urethrocystoscopy, a short segment partial penile urethral stricture was discovered. This was confirmed by retrograde urethrography and treated by dilatation.
The urethrocystoscopy done after dilatation of the stricture, revealed a mild hyperemia in the posterior urethra, otherwise healthy-looking posterior urethra. A repeat biopsy revealed no evidence of malignancy (Figures 2 and 3) .
The patient was followed up for 4 years. He had no recurrence of hematuria and urethrocystoscopy revealed a healthy-looking posterior urethra.
Discussion
We report a successful curative treatment of urethral cancer using intraurethral instillation of mitomycin-C, in a 34-year-old man, without transurethral resection or fulguration of the tumor. Six courses were given to him at weekly intervals. He did very well, however he developed a partial short segment penile urethral stricture as a complication. Some authors have similarly described success with this method, 3 but the intraurethral chemotherapy was given after initial transurethral resection of the tumor. Urethral stricture following intraurethral instillation of mitomycin C has also been described by Richard and colleagues. 8 Some urologists had treated urethral cancer with transurethral resection alone, but reported recurrence following the procedure, however cure had been achieved with intraurethral instillation of mitomycin-C after the resection. 3 Though very rare, other complications associated with the use of intraurethral instillation of mitomycin C includes: Glans necrosis (though this is seen after use of higher dose of 60 mg), necrosis of the corpus spongiosum and urethral sloughing. 9 In our patient, we treated him successfully with intraurethral instillation of Mitomycin-C, without prior resection. He was followed up for four years, and he showed no evidence of the disease recurrence. We can therefore confidently recommend this form of treatment for selected patients with low grade transitional cell cancer of the urethra.
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Conclusions
Low grade Urothelial cancer of the urethra can be successfully cured with Intraurethral instillation of mitomycin C, without prior transurethral resection. Although it is associated with some complications, they are generally rare from the reported literature.
